You Can Help
Contact
Forum
Shop
Search
Sign Up
Donate
You Can Help
What is ALS
Newly Diagnosed?
Treatments & ALS Drugs
Frequently Asked Questions
Glossary
ALS Research
Drug Discovery Engine
Pipeline of ALS Research
Precision Medicine Program
Research News
Meet Our Scientists
Translational Research
Explore Our Lab
Publications
Help Fund Treatments
Donate
Start a Fundraiser
Events
ALS Awareness
Other Ways to Give
Corporate Opportunities
Resources
ALS Forum
ALS Clinical Trials
News
ALS Town Hall
ALS TDI Community Conversations
Podcasts
About Us
History
Team
Our Supporters
Schedule a Tour
Financials
Press Room
Contact Us
You Can Help
Contact
Forum
Search
Donate
Sign Up
Your support fuels our research to #EndALS!
Donate Now
ALS Clinical Trials
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
ALS Clinical Trials
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
Quick Info
Status
This study has been completed
Phase
3
Trial Type
Double-blind placebo
Treatment Type
Injection
Randomization
Unknown
Enrollment
128
Start Date
12/1/2011
Sponsor
Mitsubishi Tanabe Pharma Corporation
Contact Information
Contact information unknown.
Locations
Japan
Enrollment Criteria
Breathing Ability
Percent lung function (
FVC
) or (
SVC
)
N/A
Months Since Onset
Number of months since first symptoms of ALS.
<24
Non-Invasive Ventilation (NIV)
Can PALS use a BiPAP in the trial?
Unknown
Diaphragm Pacer (DPS)
Can PALS use a
DPS
in the trial?
Unknown
Edaravone Usage
Can a PALS use edaravone (Radicut/Radicava) while enrolled in the trial?
Unknown
Open Label
Unknown
Update Notes
Trial completed.
6/23/2015
No significant updates.
8/25/2014
This study is active, but not currently recruiting.
8/7/2013
Enrollment criteria added.
3/27/2013
Clinical trial added.
2/28/2013
Other Information
Purpose
The primary objective of the study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip infusion once a day in the patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. The study is also to examine the safety of MCI-186 to the ALS patients.
Eligibility
Both gender 20-75. “Definite ALS” or “probable ALS” diagnosis. Can eat a meal, excrete, move alone. Less than 2 years after onset. Exclusion: Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, anamnesis of hypersensitivity to edaravone. Pregnancy or lactation, participation in other trials within 12 weeks.
Details
Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles). Drug: Placebo Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles). Drug: MCI-186 in open label phase All patients after the double blind phase may receive MCI-186 in 7th until 12th treatment - observation cycles at the patients' will.
Collaborator(s)
-
Trial Protocol as Published on Clinicaltrials.gov
NCT01492686
(First Published: 12/11/2011)
What is ALS
ALS Research
Help Fund Treatments
Resources
About Us
Contact
Forum
Shop
Search
Donate
Sign Up
What is ALS
Overview
Newly Diagnosed?
Treatments & ALS Drugs
FAQS
Glossary
Contact
Forum
Shop
Search
Donate
Sign Up
ALS Research
Overview
Drug Discovery Engine
Pipeline of ALS Research
Precision Medicine Program
Research News
Meet Our Scientists
Translational Research
Explore Our Lab
Publications
Contact
Forum
Shop
Search
Donate
Sign Up
Help Fund Treatments
Overview
Donate
Start a Fundraiser
Events
ALS Awareness
Other Ways To Give
Corporate Opportunities
Contact
Forum
Shop
Search
Donate
Sign Up
Resources
Overview
ALS Forum
ALS Clinical Trials
News
ALS Town Hall
ALS TDI Community Conversations
Podcasts
Contact
Forum
Shop
Search
Donate
Sign Up
About Us
Overview
History
Team
Our Supporters
Schedule a Tour
Financials
Press Room
Contact Us
Contact
Forum
Shop
Search
Donate
Sign Up